Altimmune announced positive Phase 2 RECLAIM trial results for its next-gen GLP-1/glucagon dual agonist pemvidutide in alcohol use disorder, showing a statistically significant reduction in heavy drinking days per week versus placebo
Pemvidutide 2.4 mg reduced heavy drinking days by 4.20 versus 2.75 in placebo, a 1.45-day placebo-adjusted difference (p=0.0014), and met key FDA-recognized secondary endpoints including two-level reduction in WHO risk drinking levels and zero heavy drinking days
The drug was generally well tolerated, with predominantly gastrointestinal side effects and a 10% discontinuation rate due to adverse events, and demonstrated a 9.1% placebo-adjusted weight loss over six months, supporting its dual utility for AUD and obesity
Sources:
Press Release of Altimmune, Inc. dated March 5, 2026 - SEC.gov
Altimmune drug cuts heavy drinking in mid-stage trial for ...
Altimmune wins FDA fast track status for alcohol use disorder therapy
Altimmune stock rises as GLP-1 cuts drinking (ALT:NASDAQ)
Altimmune To Test Investigational GLP-1–Based Obesity ...
Adding weekly GLP-1 to cognitive behavioral therapy ...
Altimmune – Investors Overview